China Resources Double-Crane PharmaceuticalLtd Gelecekteki Büyüme

Future kriter kontrolleri 1/6

China Resources Double-Crane PharmaceuticalLtd kazanç ve gelirin sırasıyla yıllık 17.3% ve 9.7% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 17% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 13.2% olacağı tahmin edilmektedir.

Anahtar bilgiler

17.3%

Kazanç büyüme oranı

17.0%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	19.4%
Gelir büyüme oranı	9.7%
Gelecekteki özkaynak getirisi	13.2%
Analist kapsamı	Low
Son güncelleme	30 Oct 2024

Gelecekteki son büyüme güncellemeleri

The China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Oct 29

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Just Reported And Analysts Have Been Lifting Their Price Targets

Mar 24

Recent updates

The China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Oct 29

China Resources Double-Crane Pharmaceutical Co.,Ltd.'s (SHSE:600062) Low P/E No Reason For Excitement

Oct 21

An Intrinsic Calculation For China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Suggests It's 49% Undervalued

Sep 30

We Think China Resources Double-Crane PharmaceuticalLtd (SHSE:600062) Can Manage Its Debt With Ease

Jul 16

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Just Reported And Analysts Have Been Lifting Their Price Targets

Mar 24

Investors Don't See Light At End Of China Resources Double-Crane Pharmaceutical Co.,Ltd.'s (SHSE:600062) Tunnel

Mar 02

Kazanç ve Gelir Büyüme Tahminleri

SHSE:600062 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CNY Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	13,252	2,159	N/A	2,600	2
12/31/2025	13,055	1,933	N/A	2,321	3
12/31/2024	12,017	1,763	N/A	1,873	3
9/30/2024	10,322	1,348	1,082	1,840	N/A
6/30/2024	10,308	1,395	1,207	1,801	N/A
3/31/2024	10,285	1,374	1,201	1,812	N/A
12/31/2023	10,222	1,333	1,026	1,631	N/A
9/30/2023	10,916	1,584	1,296	1,811	N/A
6/30/2023	10,558	1,428	1,028	1,514	N/A
3/31/2023	9,880	1,223	888	1,357	N/A
12/31/2022	9,625	1,180	890	1,416	N/A
9/30/2022	9,394	1,025	611	1,258	N/A
6/30/2022	9,392	1,078	720	1,337	N/A
3/31/2022	9,222	981	618	1,198	N/A
12/31/2021	9,112	936	849	1,341	N/A
9/30/2021	9,006	1,021	904	1,269	N/A
6/30/2021	8,987	1,046	964	1,328	N/A
3/31/2021	8,730	1,016	956	1,318	N/A
12/31/2020	8,504	1,005	1,012	1,360	N/A
9/30/2020	8,348	1,010	956	1,238	N/A
6/30/2020	8,663	971	1,068	1,323	N/A
3/31/2020	8,930	1,001	1,123	1,347	N/A
12/31/2019	9,381	1,055	1,198	1,440	N/A
9/30/2019	9,322	1,043	1,192	1,430	N/A
6/30/2019	9,003	1,024	1,195	1,428	N/A
3/31/2019	8,720	997	1,289	1,541	N/A
12/31/2018	8,225	969	1,240	1,469	N/A
9/30/2018	7,975	962	1,386	1,589	N/A
6/30/2018	7,434	905	N/A	1,406	N/A
3/31/2018	7,032	908	N/A	1,271	N/A
12/31/2017	6,422	843	N/A	1,187	N/A
9/30/2017	6,103	838	N/A	1,071	N/A
6/30/2017	5,725	801	N/A	1,107	N/A
3/31/2017	5,584	767	N/A	911	N/A
12/31/2016	5,495	714	N/A	771	N/A
9/30/2016	5,490	705	N/A	828	N/A
6/30/2016	5,414	684	N/A	775	N/A
3/31/2016	5,274	645	N/A	813	N/A
12/31/2015	5,138	661	N/A	701	N/A
9/30/2015	5,733	865	N/A	1,025	N/A
6/30/2015	5,562	832	N/A	1,016	N/A
3/31/2015	5,413	785	N/A	876	N/A
12/31/2014	5,153	737	N/A	929	N/A
9/30/2014	4,276	776	N/A	674	N/A
6/30/2014	5,184	845	N/A	539	N/A
3/31/2014	6,010	859	N/A	637	N/A
12/31/2013	6,835	871	N/A	546	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 600062 'nin tahmini kazanç büyümesi (yıllık 17.3% ) tasarruf oranının ( 2.8% ) üzerindedir.

Kazançlar ve Piyasa: 600062 şirketinin kazançlarının (yıllık 17.3% ) CN pazarından (yıllık 26.3% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: 600062 şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: 600062 şirketinin gelirinin (yıllık 9.7% ) CN pazarından (yıllık 14% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 600062 şirketinin gelirinin (yıllık 9.7% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 600062 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 13.2 %).

China Resources Double-Crane PharmaceuticalLtd Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

The China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Consensus EPS estimates increase by 11%

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Just Reported And Analysts Have Been Lifting Their Price Targets

Price target increased by 26% to CN¥24.32

Price target increased to CN¥19.26

Recent updates

The China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Third quarter 2024 earnings released: EPS: CN¥0.34 (vs CN¥0.29 in 3Q 2023)

China Resources Double-Crane Pharmaceutical Co.,Ltd.'s (SHSE:600062) Low P/E No Reason For Excitement

China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Oct 26, 2024

Investor sentiment improves as stock rises 15%

An Intrinsic Calculation For China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Suggests It's 49% Undervalued

Consensus EPS estimates increase by 11%

We Think China Resources Double-Crane PharmaceuticalLtd (SHSE:600062) Can Manage Its Debt With Ease

Dividend of CN¥0.26 announced

China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report First Half, 2024 Results on Aug 23, 2024

China Resources Double-Crane Pharmaceutical Co.,Ltd., Annual General Meeting, May 17, 2024

China Resources Double-Crane Pharmaceutical Co.,Ltd., Annual General Meeting, May 17, 2024

First quarter 2024 earnings released: EPS: CN¥0.41 (vs CN¥0.36 in 1Q 2023)

China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Apr 26, 2024

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Just Reported And Analysts Have Been Lifting Their Price Targets

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Investors Don't See Light At End Of China Resources Double-Crane Pharmaceutical Co.,Ltd.'s (SHSE:600062) Tunnel

Now 20% undervalued

China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 22, 2024

Third quarter 2023 earnings released: EPS: CN¥0.29 (vs CN¥0.24 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.39 (vs CN¥0.40 in 2Q 2022)

Price target increased by 26% to CN¥24.32

Investor sentiment improves as stock rises 18%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Price target increased to CN¥19.26

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.24 (vs CN¥0.28 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.40 (vs CN¥0.30 in 2Q 2021)

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) agreed to acquire 50.1% stake in Shenzhou Biology & Technology Co., Ltd. for RMB 501.7 million.

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) agreed to acquire 50.1% stake in Shenzhou Biology & Technology Co., Ltd. for RMB 501.7 million.

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

Now 21% undervalued

Investor sentiment improved over the past week

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) announces an Equity Buyback for 23,500,000 shares, for CNY 431.7 million.

Third quarter 2021 earnings released: EPS CN¥0.28 (vs CN¥0.31 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.30 (vs CN¥0.27 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.27 (vs CN¥0.26 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.96 (vs CN¥1.01 in FY 2019)

China Resources Double-Crane Pharmaceutical Plans to Invest in Zhejiang Biotech Firm

New 90-day low: CN¥11.83

China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report Fiscal Year 2020 Results on Mar 19, 2021

New 90-day low: CN¥11.90

New 90-day low: CN¥12.04

New 90-day low: CN¥12.51

Third quarter earnings released

New 90-day low: CN¥12.62

New 90-day low: CN¥12.77

Earnings released

New 90-day high - CN¥14.78

China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report First Half, 2020 Results on Aug 25, 2020

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin